# Preventing ovarian aging: from redox-targeted strategies to extracellular vesicle-based therapies

**Authors:** Chiara Camerano Spelta Rapini, Camila Cecilia Rojo-Fleming, Chiara Di Berardino, Alessia Peserico, Giulia Capacchietti, Umberto Tosi, Nicola Bernabò, Mauro Mattioli, Barbara Barboni

PMC · DOI: 10.3389/fragi.2026.1707614 · Frontiers in Aging · 2026-02-24

## TL;DR

This review explores how oxidative stress and inflammation accelerate ovarian aging and discusses new therapies like antioxidants and extracellular vesicles to preserve reproductive health.

## Contribution

The paper introduces extracellular vesicles as a novel cell-free therapy for preventing ovarian aging.

## Key findings

- Environmental factors like smoking and nanoplastics contribute to premature ovarian decline.
- Extracellular vesicles show preclinical potential in reducing oxidative stress and restoring ovarian function.
- Antioxidants such as melatonin and coenzyme Q10 may delay ovarian aging.

## Abstract

Ovarian aging is increasingly recognized as a dynamic and modifiable process influenced by oxidative stress, mitochondrial dysfunction, and chronic inflammation. This review outlines the mechanisms by which environmental and lifestyle factors, such as smoking, high-fat diets, endocrine-disrupting chemicals, and micro- and nanoplastics (MNPs), contribute to accelerated ovarian decline and premature reproductive senescence. The distinction between physiological aging and pathological processes such as “inflamm-aging” is discussed, with particular attention to redox imbalance and mitochondrial impairment as key drivers of follicular depletion and endocrine dysfunction. Insights from experimental models of premature ovarian insufficiency and polycystic ovary syndrome are summarized to illustrate the role of reactive oxygen species and oxidative damage. Current antioxidant-based strategies aimed at delaying ovarian aging are reviewed, including melatonin, N-acetylcysteine, coenzyme Q10, polyphenols, and vitamins C and E. Particular emphasis is placed on the emerging potential of stem cell-derived extracellular vesicles (EVs) as a novel, cell-free therapeutic approach. Preclinical evidence suggests that EVs can reduce oxidative stress, support mitochondrial function, and restore ovarian physiology. Overall, the review highlights how redox-targeted and EV-based interventions may offer promising avenues to preserve ovarian function and extend reproductive healthspan.

## Linked entities

- **Chemicals:** melatonin (PubChem CID 896), N-acetylcysteine (PubChem CID 12035), coenzyme Q10 (PubChem CID 5281915), vitamin C (PubChem CID 54670067), vitamin E (PubChem CID 14985)
- **Diseases:** polycystic ovary syndrome (MONDO:0008487)

## Full-text entities

- **Diseases:** mitochondrial dysfunction (MESH:D028361), chronic inflammation (MESH:D007249), premature ovarian insufficiency (MESH:D016649), polycystic ovary syndrome (MESH:D011085), endocrine dysfunction (MESH:D004700)
- **Chemicals:** coenzyme Q10 (MESH:C024989), polyphenols (MESH:D059808), reactive oxygen species (MESH:D017382), N-acetylcysteine (MESH:D000111), melatonin (MESH:D008550), vitamins C and E. (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12971691/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12971691/full.md

## References

177 references — full list in the complete paper: https://tomesphere.com/paper/PMC12971691/full.md

---
Source: https://tomesphere.com/paper/PMC12971691